butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of CYP3A4 inducers may perhaps decrease sufentanil degrees and efficacy, probably precipitating withdrawal syndrome in patients who have desig